Vanguard Group Inc I Mab Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.08 - $7.39 $86,994 - $208,730	28,245 Added 1.35%	2,115,277 $7.32 Million
Q4 2022 Feb 10, 2023	BUY	$3.22 - $4.86 $237,732 - $358,813	73,830 Added 3.67%	2,087,032 $8.72 Million
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $220,754 - $679,329	55,051 Added 2.81%	2,013,202 $8.07 Million
Q2 2022 Aug 12, 2022	BUY	$8.27 - $18.43 $7.89 Million - $17.6 Million	953,542 Added 94.92%	1,958,151 $22.1 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $372,801 - $1.4 Million	29,729 Added 3.05%	1,004,609 $16.3 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $1.06 Million - $1.75 Million	23,506 Added 2.47%	974,880 $46.2 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $51 Million - $75.3 Million	892,026 Added 1503.04%	951,374 $69 Million
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $2.84 Million - $4.98 Million	59,348 New	59,348 $4.98 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.